本公司将根据公司上市地股票上市规则的规定履行信息披露义务。敬请投资 者注意投资风险。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司注意到近日部分媒体有关本公司一家香港子公司（以下简称香港子公 司）被香港证券及期货事务监察委员会（以下简称香港证监会）及廉政公署（以 下简称廉署）调查的报道。经核实，2026年3月10日，香港证监会及廉署持搜查令 到访香港子公司的营业地点，带走部分文件。香港子公司一名员工曾被廉署问话。 本公司对此高度重视，将继续密切关注此事进展情况。 本公司董事会确认，截至本公告披露日，本公司及香港子公司经营情况正常， 各项业务均保持正常开展，各项经营活动均有序且合规地进行。 证券代码：600030 证券简称：中信证券 公告编号：临2026-018 中信证券股份有限公司 关于子公司相关媒体报道事宜的公告 中信证券股份有限公司董事会 2026年3月12日 ...

3月12日，中信证券公告称，公司注意到近日部分媒体报道本公司一家香港子公司被香港证监会及廉政 公署调查。经核实，2026年3月10日，香港证监会及廉署持搜查令到访香港子公司的营业地点，带走部 分文件。香港子公司一名员工曾被廉署问话。公司对此高度重视，将继续密切关注此事进展情况。公司 确认，截至公告披露日，公司及香港子公司经营情况正常，各项业务均保持正常开展。公司将根据上市 地股票上市规则的规定履行信息披露义务。 ...

Core Insights - The company Xunce Technology (03317.HK) has gained significant attention from major institutional investors following its listing on the Hong Kong Stock Exchange, with firms like Deutsche Bank and CITIC Securities initiating coverage and giving an "overweight" rating, reflecting a consensus on its long-term value in "data infrastructure + enterprise AI application platform" [1][2]. Group 1: Company Growth and Financial Projections - Xunce Technology is compared to Palantir, as both companies cover the entire data processing workflow from acquisition to application, distinguishing them from competitors that focus on single points [2]. - CITIC Securities predicts that Xunce's revenue will reach 1.28 billion, 2.33 billion, and 3.45 billion yuan in 2025, 2026, and 2027, respectively, with year-on-year growth rates of 103%, 82%, and 48% [3]. - The company is expected to achieve profitability in 2026 with a net profit of 272 million yuan, increasing to 841 million yuan in 2027, indicating a maturation of its business model and the realization of scale effects [3]. Group 2: Market Opportunities and Product Development - The demand for AI Agents is surging, marking a shift from conversational to task-oriented execution, which emphasizes the importance of real-time data flow, reliability, and governance for agent effectiveness [4]. - Xunce has launched the FeedClaw platform to provide high-quality data for AI agents, ensuring security and compliance through features like permission isolation and data auditing [4]. - The current market penetration for real-time data infrastructure in China is only about 3.6%, indicating substantial growth potential as the enterprise-level real-time data systems are still in their early stages [4]. Group 3: Stock Performance and Market Position - Beyond fundamentals, Xunce Technology was officially included in the Hong Kong Stock Connect on March 9, 2026, contributing to a stock price increase of over 180% year-to-date, with a market capitalization exceeding 55 billion HKD at one point [5].

Company Overview - XunCe Technology (03317) is a leading real-time data infrastructure provider in China, focusing on real-time data infrastructure and analysis solutions, with a market share of 3.4% in the overall market and 11.6% in the asset management sector, ranking fourth and first respectively [2] - The company was established in April 2016 and is set to be listed on the Hong Kong Stock Exchange on December 30, 2025 [2] Industry Analysis - The real-time data infrastructure and analysis market in China is experiencing rapid penetration, benefiting from data factor policy dividends and the urgent need for digital transformation in downstream industries, with a projected double-digit growth over the next five years [2] - The market size is expected to grow from RMB 187 billion in 2024, with a compound annual growth rate (CAGR) of 46.1% from 2020 to 2024, and is projected to reach RMB 505 billion by 2029, driven by policy support and the demand for digital transformation across industries [2] Growth Potential - The company is expected to achieve profitability by 2026, supported by solid fundamentals and diversified revenue streams [4] - Revenue from the asset management sector is projected to decrease from 74.4% in 2022 to 38.7% by 2024, while contributions from non-asset management sectors are expected to rise to 61.3% by 2024, indicating successful diversification [4] Financial Projections and Valuation - Revenue forecasts for the company from 2025 to 2027 are estimated at RMB 1.28 billion, RMB 2.33 billion, and RMB 3.45 billion, with growth rates of 103%, 82%, and 48% respectively [5] - The company is expected to maintain high gross margins of 71.6%, 73.5%, and 75% from 2025 to 2027, with projected net profits of RMB -1.30 billion, RMB 2.72 billion, and RMB 8.41 billion [5] - A target market capitalization of HKD 51.7 billion is set for 2026, corresponding to a target price of HKD 160, representing a 13% upside from the current price, with an initial "Buy" rating [5]

Group 1 - The core viewpoint of the news is that Dize Pharmaceutical (688192.SH) is currently experiencing a decline in stock price, with a closing price of 49.19 yuan and a drop of 3.00%, resulting in a total market value of 22.855 billion yuan [1] - Dize Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, 2021, issuing 40.001 million shares at a price of 52.58 yuan per share [1] - The total funds raised from the initial public offering (IPO) amounted to 2.103 billion yuan, with a net amount of 1.987 billion yuan after deducting issuance costs, exceeding the original plan by 203 million yuan [1] - The company planned to use the raised funds of 1.783 billion yuan for new drug research and development projects and to supplement working capital [1] - The lead underwriter for the IPO was CITIC Securities Co., Ltd., with representatives Ding Yuan and Peng Liu, and the co-underwriter was Huatai United Securities Co., Ltd. [1] Group 2 - According to the verification report issued by Lixin Accounting Firm, the latest issuance involved 14 recipients at a price of 43.00 yuan per share, raising a total of approximately 1.799 billion yuan [2] - After deducting non-tax issuance costs of approximately 22.44 million yuan, the net amount raised was approximately 1.773 billion yuan [2] - Dize Pharmaceutical has raised a total of approximately 3.899 billion yuan from two fundraising rounds [3]

Group 1 - The core viewpoint of the article highlights the recent financial performance and stock activity of Baize Medical (02609) [1] Group 2 - On March 11, Baize Medical's shareholders deposited stocks worth HKD 289 million into CITIC Securities Brokerage Hong Kong, representing 6.66% of the total [1] - For the six months ending June 30, 2025, Baize Medical reported revenue of RMB 575 million, reflecting a year-on-year increase of 0.66% [1] - The company experienced a shareholder loss of RMB 27.62 million, which represents a year-on-year increase of 139.18%, with a basic loss per share of RMB 0.02 [1]

（文章来源：第一财经） 中信证券研报表示，美国2月CPI全面符合预期，核心通胀表现温和，不过市场焦点已不在此份有些"过 时"的数据上。在数周后伊朗冲突缓和或市场反应钝化的基准情形下，我们预计美国CPI同比增速将在3 月和4月分别因油价上涨和租金通胀补偿性上升而走高，此后在3%附近波动。美联储不必对油价波动过 度反应，美元近期可能保持偏强震荡，十年美债收益率缺乏充足下行空间。 ...

Core Viewpoint - The report from CITIC Securities indicates that the U.S. February CPI met expectations, with core inflation showing moderate performance, but market focus has shifted away from this somewhat "outdated" data [1] Group 1: Inflation Trends - It is anticipated that the U.S. CPI year-on-year growth will rise in March and April due to increases in oil prices and compensatory rises in rental inflation, before fluctuating around 3% thereafter [1] - The core inflation performance is described as mild, suggesting that underlying inflation pressures may not be as severe as previously feared [1] Group 2: Market Reactions - The Federal Reserve is not expected to overreact to fluctuations in oil prices, indicating a more measured approach to monetary policy [1] - The U.S. dollar is likely to maintain a strong and volatile trend in the near term, while the ten-year U.S. Treasury yield lacks sufficient downward space [1]

Core Viewpoint - CITIC Securities experienced a slight decline of 0.11% on March 11, with a trading volume of 2.305 billion yuan, indicating a stable market presence despite minor fluctuations [1][4]. Financing and Margin Trading - On March 11, CITIC Securities had a financing buy amount of 358 million yuan, with a repayment of 273 million yuan, resulting in a net financing purchase of 85.77 million yuan [1][4]. - The total margin trading balance reached 19.38 billion yuan, with the financing balance at 19.36 billion yuan, accounting for 6.09% of the circulating market value, which is above the 90th percentile of the past year [1][4]. - In terms of securities lending, CITIC Securities repaid 124,900 shares and sold 16,600 shares, with a selling amount of 433,300 yuan, while the lending balance was 18.86 million yuan, below the 30th percentile of the past year [1][4]. Company Overview - CITIC Securities, established on October 25, 1995, and listed on January 6, 2003, is headquartered in Shenzhen and Beijing, with its main business activities including securities brokerage, underwriting, asset management, and proprietary trading [5]. - The revenue composition is as follows: securities investment (43.88%), brokerage services (28.21%), asset management (18.21%), underwriting (6.22%), and other services (3.49%) [5]. Financial Performance - For the period from January to September 2025, CITIC Securities reported a revenue of 55.815 billion yuan, reflecting a year-on-year growth of 20.96%, and a net profit attributable to shareholders of 23.159 billion yuan, up by 37.86% [2][5]. - The company has distributed a total of 93 billion yuan in dividends since its A-share listing, with 26.306 billion yuan distributed over the past three years [3][5]. Shareholder Structure - As of September 30, 2025, CITIC Securities had 669,400 shareholders, an increase of 1.64% from the previous period, with an average of 18,192 circulating shares per shareholder, a decrease of 1.61% [2][6]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 500.1 million shares, a decrease of 83.4469 million shares from the previous period, while the Guotai CSI All-Share Securities Company ETF is a new entrant holding 252 million shares [6].

每经头条（nbdtoutiao）——专访商务部原副部长王炳南：中国将以服务业为重点扩大开放领域，有序 扩大电信、医疗、教育等领域自主开放 （记者 王瀚黎） 每经AI快讯，壹网壹创（SZ 300792，收盘价：38.86元）发布公告称，2026年3月11日下午 13:30~14:30，壹网壹创接受中信证券等投资者调研，公司副总经理、董事会秘书高凡，IR 总监杨锦明 参与接待，并回答了投资者提出的问题。 ...